Abstract: A hearing protection earplug having a shell worn at least in part in a user's ear canal, an active unit having an acoustic output transducer and an arrangement for producing output audio signals for said output transducer, and a detachable connection of the active unit to said shell, the shell including a sound passage extending between an outer opening of said shell and an inner sound output opening of said shell and having a valve mechanism which is moveable, upon connecting said active unit to said shell, from a closed position acoustically closing said sound passage into an open position acoustically opening said sound passage, said valve mechanism being biased towards said closed position when said active unit is removed from said shell, and wherein said output transducer is acoustically connected to said sound output opening via said sound passage when said active unit is connected to said shell.

Abstract: The invention relates to a hearing protection earplug comprising a shell (10) to be worn at least in part in a user's ear canal, said shell being adapted to provide for a mechanical acoustic attenuation of at least 10 dB averaged over the audible frequency range when worn by the user, an active unit (12) comprising an acoustic output transducer (26) and means (30, 32, 60) for producing output audio signals for said output transducer, and means (34, 36, 38, 40, 56, 58, 80, 82, 84) for detachably connecting said active unit to said shell, wherein said shell comprises a sound passage (16, 16?) extending between an outer opening (14) of said shell and an inner sound output opening (18, 18?) at the distal end of said shell and comprising valve means (20, 120, 320) which are moveable, upon connecting said active unit to said shell, from a closed position in which said valve means acoustically close said sound passage into an open position in which said valve means acoustically open said sound passage, said valve me

Abstract: The use of bacterial lipases which show an immunological cross-reaction with the antibodies to the lipase produced by the microorganism Pseudomonas spec. DSM 6483 and/or Pseudomonas cepacia IAM 1057 for producing drugs for the therapy of maldigestion is described.

Abstract: A process for increasing the riboflavin content in spray-dried discharges from riboflavin fermentations comprises inducing the lysis of the cells contained in the fermentation discharge by specific production or activation of enzymes which break down the cell walls and proteins. This autolysis can be induced in the riboflavin-producing strains of Ashbya gossypii, Eremothecium ashbyii and other microorganisms by incubation at from 35 to 55.degree. C. with substantial exclusion of oxygen for from 6 to 28 hours.

Abstract: The promoter region of the A. Gossypii gene which encodes translation elongation factor EF-1.alpha. is described. The promoter can be employed for protein synthesis.

Abstract: The use of bacterial lipases which show an immunological cross-reaction with the antibodies to the lipase produced by the microorganism Pseudomonas spec. DSM 6483 and/or Pseudomonas cepacia IAM 1057 for producing drugs for the therapy of maldigestion is described.

Abstract: The use of bacterial lipases which show an immunological cross-reaction with the antibodies to the lipase produced by the microorganism Pseudomonas spec. DSM 6483 and/or Pseudomonas cepacia IAM 1057 for producing drugs for the therapy of maldigestion is described.